eBAT Compassionate Care
Study Title: Compassionate use of recombinant bispecific angiotoxin simultaneously targeting EGFR and uPAR (eBAT Compassionate Care)
Current Status: Open and enrolling
Principal Investigator: Jaime Modiano, VMD, PhD
Co-Investigator: Antonella Borgatti, DVM, MS
Contacts: Dr. Modiano, [email protected]
Amber Winter, Research Technician Specialist, [email protected], 612-624-1352
STUDY UPDATE: We will not be enrolling new cases until May 1. We will update the web page as we get closer to May 1 to let people know if we will start enrolling again or if we will delay further based on information related to COVID-19.
Study purpose and design:
Hemangiosarcoma is a type of sarcoma that is difficult to treat because of its aggressive behavior and rapid progression after diagnosis. We have shown that a novel EGF bispecific ligand targeted angiotoxin (eBAT) is safe in dogs and that it can kill hemangiosarcoma cells in the laboratory. We have treated 50 pet dogs with eBAT. The results from our previous trials show that eBAT doubled 6-month survival of dogs with hemangiosarcoma, from 38% to 77%, and more than doubled the expected 1-year survival, from about 15% to about 40%. Results of this study will provide information to develop a therapy for both dogs and humans with this incurable disease.
Dogs eligible for compassionate care with eBAT:
- Have diagnosed and staged hemangiosarcoma (HSA)
- Performance score 0 or 1
- Have an adequate supply of red blood cells (≥ 22% packed cell volume)
- Have no severe comorbidities such as advanced kidney, liver or heart disease, or problems with blood clotting
- Not taking cyclophosphamide
- Not taking any alternative medications as therapy for their HSA
- May be taking prednisone and/or nonsteroidal anti-inflammatory drugs (NSAIDS) to manage other chronic conditions
(Note – diagnostics performed elsewhere may be acceptable upon review. The abdominal ultrasound (required for staging) is required to be performed by a board-certified Radiologist. Thoracic radiographs will need to be reviewed by a board-certified radiologist.)
Owners must agree to the procedures required for their dog. Dogs must be screened at the University of Minnesota Veterinary Medical Center (VMC) prior to enrollment. The final decision to treat a dog will be at the discretion of the clinician after the screening appointment. Treatment with eBAT consists of 3 days, every other day, for a week (up to 8 days). Recheck and restaging appointments occur on Day 8, 21, 42, 63, 84, 105, 152, 180 and every 2-3 months thereafter. Rechecks and chemotherapy may be performed at the VMC or at the owner's veterinarian or oncology specialist.
Treatment with eBAT will be done exclusively at the University of Minnesota Veterinary Medical Center in St. Paul, MN
Costs of the study:
The costs of eBAT are covered by the study. All other costs are the responsibility of the owner. Depending upon the stage of disease and procedures required, owners can expect costs between $2,000 and $20,000. The minimum costs of $2,000 are for screening and eBAT treatment at the VMC only and do not include diagnosis and imaging. The high end costs assume the dog has all staging, chemotherapy and follow up visits at the VMC.
Steps to enroll:
We ask owners interested in enrolling their pet to do the following:
- Read the consent form below for full details
- If your dog qualifies, click 'Enroll Here' and complete the enrollment survey.
For questions, please contact Dr. Modiano above.